The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece
Abstract Gout is an autoinflammatory disease caused by monosodium urate mono hydrate crystal deposition in tissues or the supersaturation
Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence
Abstract Many patients with gouty arthritis experience frequent flares and have comorbidities that may limit their anti-inflammatory treatment options
The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece
Abstract Gout is an autoinflammatory disease caused by monosodium urate mono hydrate crystal deposition in tissues or the supersaturation
Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence
Abstract Many patients with gouty arthritis experience frequent flares and have comorbidities that may limit their anti-inflammatory treatment options